259 reports of this reaction
1.7% of all ROMOSOZUMAB AQQG reports
#15 most reported adverse reaction
INJECTION SITE ERYTHEMA is the #15 most commonly reported adverse reaction for ROMOSOZUMAB AQQG, manufactured by Amgen, Inc. There are 259 FDA adverse event reports linking ROMOSOZUMAB AQQG to INJECTION SITE ERYTHEMA. This represents approximately 1.7% of all 15,195 adverse event reports for this drug.
Patients taking ROMOSOZUMAB AQQG who experience injection site erythema should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INJECTION SITE ERYTHEMA is a less commonly reported adverse event for ROMOSOZUMAB AQQG, but still significant enough to appear in the safety profile.
In addition to injection site erythema, the following adverse reactions have been reported for ROMOSOZUMAB AQQG:
The following drugs have also been linked to injection site erythema in FDA adverse event reports:
INJECTION SITE ERYTHEMA has been reported as an adverse event in 259 FDA reports for ROMOSOZUMAB AQQG. This does not prove causation, but indicates an association observed in post-market surveillance data.
INJECTION SITE ERYTHEMA accounts for approximately 1.7% of all adverse event reports for ROMOSOZUMAB AQQG, making it a notable side effect.
If you experience injection site erythema while taking ROMOSOZUMAB AQQG, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.